Drug Profile
Doranidazole - Shuttle Pharmaceuticals
Alternative Names: PR 350; RP 343Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Kyoto University; POLA PHARMA
- Developer POLA PHARMA; Shuttle Pharmaceuticals
- Class Imidazoles; Radiosensitisers; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-0 development in Pancreatic-cancer in USA (IV)
- 10 Jan 2020 No development reported - Phase-II for Non-small cell lung cancer in Japan (IV)
- 10 Jan 2020 No development reported for Non-small cell lung cancer in USA (IV)